# Biosimilar Contract Manufacturing Market

> Biosimilar Contract Manufacturing Market Research Report Information By Product (Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins), By Production Technology (Mammalian and Non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 14.9%
- **2025:** USD 12.82 Billion
- **2035:** USD 51.42 Billion
- **Key Players:** Samsung Biologics, Lonza Group, Boehringer Ingelheim BioXcellence, WuXi Biologics, Fujifilm Diosynth Biotechnologies, Celltrion, Rentschler Biopharma, AGC Biologics

**Report ID:** MRFR/Pharma/10382-HCR · **Pages:** 128 · **Author:** Rahul Gotadki & Nidhi Mandole · **Last Updated:** September 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/biosimilar-contract-manufacturing-market-11903

---

## Market Summary

The Global Biosimilar Contract Manufacturing Market size was valued at USD 7.729 Billion in 2024, and the market is projected to grow from USD 9.189 Billion in 2025 to USD 51.9 Billion by 2035, registering a CAGR of 18.9% during the forecast period 2025–2035. North America led the market in 2024 with over 45% share, generating around USD 3.48 Billion in revenue.
 
Rising demand for cost-efficient biologics and increasing patent expirations of blockbuster drugs are key growth drivers, encouraging pharmaceutical companies to outsource biosimilar production to specialized contract manufacturers, enhancing scalability, reducing costs, and accelerating time-to-market for advanced therapeutic solutions globally.
 
According to WHO, biologics account for nearly 50% of global pharmaceutical spending, while biosimilars can reduce treatment costs by 20–30%, significantly improving access; additionally, over $80 billion worth of biologics are expected to lose patent protection globally, driving biosimilar manufacturing demand.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Biologic patent cliff 2026–2032 | 4.1 | Global | Short-term (≤2 yr) | [3] |
| Payer cost-containment mandates | 2.8 | US, EU, Japan | Short-term (≤2 yr) | [2] |
| Capital avoidance by mid-cap sponsors | 2.4 | Global | Medium-term (2–4 yr) | [8] |
| Single-use and perfusion intensification | 2.2 | NA, EU, Korea | Medium-term (2–4 yr) | [5] |
| Regulatory streamlining of comparability | 1.9 | EU, US | Medium-term (2–4 yr) | [9] |
| Emerging-market access programs | 1.3 | APAC, LATAM, MEA | Long-term (≥4 yr) | [10] |
| Onshoring and supply-chain resilience policy | 0.9 | US, EU, India | Long-term (≥4 yr) | [11] |

### The Patent Cliff Is the Demand Engine

### Payer Economics Force Cost Discipline

Medicare's negotiated maximum fair prices took effect in January 2026 for the first ten selected drugs, with seven biologics in the second tranche [[2]](https://cms.gov). European tender systems already clear biosimilar insulins and anti-TNFs at 65–80% discounts to originator list price. At those realisations, a sponsor needs cost of goods below USD 40 per gram of drug substance — achievable at a specialist contract site running 6 g/L titres, rarely achievable in a captive plant at 40% utilisation. Procurement teams have responded by shifting roughly 71% of new biosimilar programs to external manufacture [[8]](https://.com).

### Process Intensification Rewrites Unit Economics

Perfusion and high-density fed-batch processes have lifted typical monoclonal antibody titres from 2–3 g/L to 6–9 g/L over eight years [[5]](https://lonza.com). Lonza's Visp facility and Samsung Biologics Plant 5 both deploy intensified trains that deliver the output of a legacy 15,000-litre stainless line from a 4,000-litre single-use suite. Capital per annual kilogram falls by 38–45%, and changeover between programs drops from 12 weeks to under four. For contract manufacturers, that means more programs per suite per year — the single most powerful margin lever available.

### Regulatory Convergence Shortens Development

EMA's 2024 reflection paper on tailored clinical development signalled that comparative efficacy trials may be waived where analytical and PK similarity is robust [[9]](https://ema.europa.eu). FDA followed with draft guidance in 2025 easing switching-study requirements for interchangeability. Removing a Phase III comparative trial saves a sponsor USD 60–100 million and 24 months — but raises the analytical burden, which flows straight to contract laboratories.

## Restraints

## Restraints Impact Analysis

The weightings below represent estimated drag on growth and are directional. They reflect analyst judgement on how severely each constraint suppresses realised demand within the Biosimilar Contract Manufacturing Market rather than a subtractive calculation.

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Capacity overbuild and price erosion. | 2.3 | Global | Medium-term (2–4 yr) | [6] |
| Tech transfer complexity and failure risk | 1.7 | Global | Short-term (≤2 yr) | [12] |
| Skilled bioprocess talent shortage | 1.4 | US, EU, Korea | Medium-term (2–4 yr) | [13] |
| Geopolitical restrictions on cross-border supply | 1.1 | US–China corridor | Short-term (≤2 yr) | [11] |
| Raw material and resin single-sourcing | 0.8 | Global | Long-term (≥4 yr) | [14] |

### Overcapacity Is a Real Risk After 2028

Announced global mammalian capacity expansions point to significant pipeline growth through the late 2020s. Industry demand modelling suggests that utilization could face downward pressure if a substantial portion of this new infrastructure comes online on schedule. Historically, excess capacity and empty suites trigger heightened price competition, leading to noticeable gross margin compression for contract manufacturers when industry utilization dips.

### Technology Transfer Remains the Failure Point

A notable share of biosimilar tech transfers encounter engineering hurdles because glycosylation profiles can drift outside the required comparability corridor during scale-up. Each repeat campaign involves substantial financial costs and timeline extensions. To mitigate this, sponsors increasingly negotiate accountability clauses into master service agreements, shifting risk onto manufacturers and impacting effective realized pricing.

### Talent Scarcity Constrains Commissioning

Widespread labor shortages of qualified upstream and downstream process engineers continue to challenge operations across the US and Europe. Consequently, new manufacturing suites frequently experience commissioning delays solely due to staffing constraints and hiring bottlenecks.

## Opportunities

## Biosimilar Contract Manufacturing Market Opportunities

### Subcutaneous and High-Concentration Formulations

Originators are converting flagship [antibodies](https://www.marketresearchfuture.com/reports/antibodies-market-20684) to subcutaneous presentations to extend franchise life. Follow-on developers must match those formats, which demand 150–200 mg/mL formulation expertise, viscosity control and specialised device fill lines. Few contract sites offer this today. Manufacturers investing in high-concentration platforms can command 20–30% pricing premiums within the Biosimilar Contract Manufacturing Market.

### Emerging-Market Capacity Partnerships

India, Brazil and Saudi Arabia are all funding domestic biologics capability. Brazil's PDP technology-transfer scheme and Saudi Arabia's Vision 2030 localisation targets both offer guaranteed offtake in exchange for in-country manufacture [[10]](https://who.int)[[15]](https://gov.br/saude). A joint-venture site in Riyadh or Hyderabad captures tender volume that no export model can reach.

### Analytics-as-a-Service and Data Monetisation

Comparability packages generate enormous structured datasets. Contract organisations that license anonymised process-analytics benchmarks, predictive glycan-profile models and digital-twin process libraries create recurring revenue independent of bioreactor hours. Several providers now bundle these as premium biosimilar CDMO services priced on subscription rather than per-batch terms.

### End-to-End Integrated Programs

Sponsors increasingly prefer one accountable partner from cell-line development through commercial fill-finish. Integrated wins carry contract values three to five times higher than discrete service awards and lock in eight-to-twelve-year relationships, materially raising switching costs across the Biosimilar Contract Manufacturing Market.

### Biobetters and Next-Wave Modalities

Antibody-drug conjugates and bispecifics approaching expiry after 2032 need conjugation and dual-chain expression capability. Early investment positions manufacturers for a second growth wave.

## Future Outlook

## Biosimilar Contract Manufacturing Market Future Outlook

### Digital Twins and Autonomous Bioprocessing

Model-predictive control on perfusion bioreactors is moving from pilot to GMP. Plants running closed-loop nutrient feedback report 11–15% titre gains and materially tighter glycan consistency. By 2032, expect the majority of new suites in the Biosimilar Contract Manufacturing Market to commission with digital-twin validation packages rather than purely empirical process characterisation [[20]](https://ispe.org).

### Platform Economics and Modality Specialisation

Generalist capacity will commoditise. Winners will specialise — one manufacturer owning high-concentration antibody formulation, another owning microbial peptides, a third owning conjugation chemistry. Specialisation supports 300–500 basis points of gross margin above generalist benchmarks.

### Continuous Manufacturing Reaches Commercial Scale

End-to-end continuous processing, connecting perfusion upstream to periodic-counter-current chromatography downstream, eliminates hold steps and shrinks facility footprint by roughly 60%. FDA's Framework for Advanced Manufacturing Technologies designation is accelerating approvals for these lines [[21]](https://fda.gov).

### Sustainability Becomes a Contract Criterion

Single-use technology cut water and cleaning-chemical consumption sharply but created a plastics burden of roughly 400 tonnes annually per large site. European sponsors now score Scope 3 emissions in vendor selection, and CSRD reporting obligations extend that scrutiny down the supply chain. Carbon intensity per gram is becoming a genuine competitive variable in the Biosimilar Contract Manufacturing Market [[22]](https://ec.europa.eu).

## Segment Insights

## Biosimilar Contract Manufacturing Market Segmentation

Segment structure across the Biosimilar Contract Manufacturing Market follows the molecular composition of the off-patent pipeline more than any technology preference.

### By Production Technology

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Mammalian | 74.5% share | Antibody and fusion protein dominance |
| Microbial | 25.5% share | Insulins, peptides, non-glycosylated proteins |

Mammalian expression dominates the Biosimilar Contract Manufacturing Market because CHO cells remain the only practical route to human-like glycosylation at scale. Microbial systems retain a durable niche: E. coli produces insulin glargine and filgrastim at a fraction of mammalian cost, and Pichia-based platforms are gaining ground for aglycosylated fragments.

### By Product

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Recombinant Glycosylated Proteins | USD 6.34 Billion | Oncology antibody expiries |
| Recombinant Non-glycosylated Proteins | 38.6% share | Insulin and growth factor volume |
| Recombinant Peptides | 15.8% CAGR | GLP-1 and teriparatide follow-ons |

Glycosylated proteins lead the Biosimilar Contract Manufacturing Market on value because comparability demands on glycan profiles make them the most analytically intensive — and therefore highest-priced — programs to manufacture. Peptides grow fastest as semaglutide-class molecules approach expiry in select jurisdictions.

### By Application

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Oncology | 42.8% share | Trastuzumab, bevacizumab, rituximab cohorts |
| Chronic & Autoimmune Diseases | USD 3.09 Billion | Anti-TNF and IL-inhibitor expiries |
| Blood Disorders | 12.3% share | Epoetin and filgrastim demand |
| Infectious Diseases | 16.4% CAGR | Antiviral antibody development |
| Growth Hormone Deficiency | USD 0.71 Billion | Somatropin volume in emerging markets |
| Other Applications | 5.4% share | Ophthalmology, fertility |

Oncology holds its lead in the Biosimilar Contract Manufacturing Market largely through checkpoint inhibitors entering the follow-on pipeline. Chronic and autoimmune indications generate steadier volumes, since patients remain on therapy for years and demand forecasting is correspondingly more reliable.

### By Service Type

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Upstream Processing | 35.2% share | Cell-line and bioreactor capacity |
| Downstream Processing | USD 3.72 Billion | Purification and chromatography scale |
| Fill & Finish Operations | 16.1% CAGR | Prefilled syringe and autoinjector demand |
| Analytical & QC Studies | 12.4% share | Comparability and stability testing |
| Packaging & Labelling | USD 0.56 Billion | Multi-market serialisation |

Upstream work commands the largest slice of the Biosimilar Contract Manufacturing Market because it consumes the most capital equipment and the most calendar time. Fill and finish grows fastest as device-integrated presentations replace vials across the biosimilar portfolio.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Share of Global Revenue (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 41.5% | Interchangeability filings, onshoring incentives |
| Europe | 27.0% | Tender-driven volume, tailored comparability |
| Asia-Pacific | 22.8% | Greenfield capacity, cost leadership |
| South America | 5.2% | Public procurement, technology transfer |
| Middle East & Africa | 3.5% | Localisation mandates, access programs |
| Total | 100.0% | — |

Regional distribution within the Biosimilar Contract Manufacturing Market reflects where regulatory approval density, capital availability and skilled bioprocess labour intersect.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| US | 84.6% of regional revenue | FDA interchangeability designations |
| Canada | USD 0.48 Billion | pCPA biosimilar switching policies |
| Mexico | 15.7% CAGR | COFEPRIS pathway modernisation |

The United States anchors the Biosimilar Contract Manufacturing Market through sheer approval volume — FDA has licensed more than 65 [biosimilars](https://www.marketresearchfuture.com/reports/biosimilars-market-1329), with 2025 filings running at record pace [[1]](https://fda.gov). CHIPS-style onshoring logic has spread to biologics: the 2024 BIOSECURE legislative push made several large sponsors dual-source away from Chinese sites, redirecting an estimated USD 1.4 billion in annual contract spend toward US and European capacity [[11]](https://congress.gov).

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 24.8% of regional revenue | Dense CDMO cluster, AMNOG pricing |
| UK | USD 0.55 Billion | MHRA streamlined biosimilar route |
| France | 14.2% CAGR | France 2030 bioproduction fund |
| Italy | 8.1% of regional revenue | AIFA regional tender volume |
| Spain | USD 0.24 Billion | Andalusian switching programs |
| Nordic Countries | 15.4% CAGR | Centralised procurement efficiency |
| Russia | 4.3% of regional revenue | Domestic substitution policy |
| Rest of Europe | USD 0.67 Billion | CEE cost-competitive capacity |

Europe's advantage is procurement scale. Danish and Norwegian tenders achieve biosimilar penetration above 90% within twelve months of launch, giving sponsors predictable volume that translates directly into firm capacity reservations [[16]](https://ec.europa.eu). France 2030 has allocated roughly EUR 800 million to bioproduction infrastructure, explicitly targeting the reshoring of essential medicine manufacture [[17]](https://gouvernement.fr).

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | 29.5% of regional revenue | NMPA approvals, domestic scale |
| India | USD 0.51 Billion | PLI scheme, cost leadership |
| Japan | 14.8% CAGR | MHLW biosimilar promotion targets |
| South Korea | 21.2% of regional revenue | Songdo mega-capacity cluster |
| ASEAN | USD 0.23 Billion | Regional harmonisation efforts |
| Rest of Asia-Pacific | 16.9% CAGR | Australia, Taiwan specialist sites |

Asia-Pacific is where the Biosimilar Contract Manufacturing Market grows fastest, at 17.6% annually. South Korea's Songdo district alone holds over 900,000 litres of installed mammalian capacity, and Samsung Biologics' Plant 5 added 180,000 litres in 2025 [[4]](https://samsungbiologics.com). India's Production Linked Incentive scheme for pharmaceuticals has disbursed incentives against roughly USD 2.1 billion of committed biologics investment [[18]](https://pharmaceuticals.gov.in).

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58.2% of regional revenue | PDP technology transfer partnerships |
| Argentina | USD 0.14 Billion | ANMAT regional export hub role |
| Rest of South America | 15.1% CAGR | Colombia, Chile access expansion |

Brazil's Productive Development Partnership model trades guaranteed Ministry of Health purchasing for local technology transfer, and biosimilar trastuzumab and rituximab have both moved through it [[15]](https://gov.br/saude). Contract manufacturers willing to accept a decade-long local partner obligation gain access to procurement volumes that bypass conventional tender competition entirely.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 27.5% of regional revenue | Vision 2030 localisation quota |
| UAE | USD 0.09 Billion | Free-zone biologics investment |
| South Africa | 16.2% CAGR | SAHPRA capacity strengthening |
| Egypt | 12.4% of regional revenue | Universal health insurance rollout |
| Rest of MEA | USD 0.08 Billion | Gulf cooperative procurement |

Saudi Arabia's National Unified Procurement Company now applies a local-content preference of up to 20% in bid scoring, which has drawn several international manufacturers into joint ventures near King Abdullah Economic City [[19]](https://nupco.com). Africa's broader picture depends on the African Medicines Agency reaching operational maturity — until then, regulatory fragmentation caps regional scale.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration is intense. The estimated HHI is around 1,450, and the top five suppliers account for roughly 52–58% of the global outsourced revenue. The Biosimilar Contract Manufacturing Market rapidly divides into regional specialists and single-modality firms below that tier. Scale advantages are real but not absolute – analytical depth and regulatory track record can trump raw litreage in vendor selection.

| Company | Est. Revenue Share Range | Key Offerings for Biosimilar Contract Manufacturing Market | Strategic Positioning |
| --- | --- | --- | --- |
| Samsung Biologics | ~17–21% | Large-scale mammalian, fill-finish, cell-line development | Capacity leader; Songdo mega-plant model |
| Lonza Group | ~12–15% | Mammalian, microbial, bioconjugation, drug product | Broadest modality coverage globally |
| Boehringer Ingelheim BioXcellence | ~7–10% | Mammalian, microbial, process characterisation | Deep biosimilar regulatory heritage |
| WuXi Biologics | ~6–9% | Integrated discovery-to-commercial, perfusion | Cost-competitive; navigating geopolitics |
| Fujifilm Diosynth Biotechnologies | ~5–8% | Mammalian, microbial, continuous processing | Aggressive multi-site expansion |
| Celltrion | ~4–6% | Antibody manufacture, in-house biosimilar portfolio | Vertically integrated sponsor-manufacturer |
| Rentschler Biopharma | ~3–5% | Mammalian, formulation, analytics | Mid-scale European specialist |
| AGC Biologics | ~3–4% | Mammalian, microbial, plasmid | Multi-continent flexible capacity |
| KBI Biopharma | ~2–4% | Cell-line development, analytical characterisation | Early-phase and comparability strength |
| Chime Biologics | ~2–3% | Cell-line, clinical and commercial supply | China-based biosimilar specialist |
| ProBioGen | ~1–3% | Glycoengineering, cell-line technology | Technology licensing plus manufacture |
| Binex Co., Ltd. | ~1–2% | Mammalian manufacture, aseptic fill | Korean mid-tier provider |

## Recent News & Developments

## Recent News & Developments

- Samsung Biologics (April 2025): Completed Plant 5 at Songdo, adding 180,000 litres and lifting total capacity above 780,000 litres — the largest single site globally [[4]](https://samsungbiologics.com)
- Lonza (January 2025): Closed acquisition of the Vacaville, California biologics site from Roche for approximately USD 1.2 billion, adding 330,000 litres of US mammalian capacity [[5]](https://lonza.com)
- FDA (June 2025): Issued draft guidance easing switching-study requirements for interchangeable biosimilars, reducing typical development cost by an estimated USD 40–60 million per program [[1]](https://fda.gov)
- Fujifilm Diosynth (October 2024): Opened its Holly Springs, North Carolina facility following a USD 3.2 billion commitment, with eight 20,000-litre bioreactors [[6]](https://fujifilm.com)
- EMA (March 2024): Published its reflection paper supporting tailored clinical development, signalling that comparative efficacy trials may be waived in defined circumstances [[9]](https://ema.europa.eu)
- Celltrion (September 2024): Announced a USD 1.9 billion multi-year capital plan covering a fourth plant and expanded fill-finish capability [[23]](https://celltrion.com)
- Chime Biologics and Kings Pharm (September 2023): Entered a strategic partnership spanning cell-line development, process development and global commercial supply [[24]](https://chimebiologics.com)
- Boehringer Ingelheim (July 2024): Committed EUR 500 million to expand its Biberach biologics site, targeting intensified perfusion trains for follow-on antibodies [[25]](https://boehringer-ingelheim.com)

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global outsourced development and manufacture of biosimilar drug substance and drug product |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 14.9% (2026–2035) |
| Market Size Checkpoints | USD 12.82 Billion (2025); USD 14.73 Billion (2026); USD 51.42 Billion (2035) |
| Fastest Growing Segments | Recombinant Peptides (product); Fill & Finish Operations (service); Asia-Pacific (geography) |
| Companies Profiled | Samsung Biologics, Lonza, Boehringer Ingelheim BioXcellence, WuXi Biologics, Fujifilm Diosynth, Celltrion, Rentschler Biopharma, AGC Biologics, KBI Biopharma, Chime Biologics, ProBioGen, Binex |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: What contract structures best protect sponsors entering the Biosimilar Contract Manufacturing Market?**
A: Take-or-pay reservations with tiered volume flexibility work best. Sponsors should negotiate comparability-failure remedies and cap batch-failure liability at a defined multiple of batch price [12].

**Q: How should a buyer evaluate analytical capability during vendor selection?**
A: Request the vendor's glycan characterisation panel, orthogonal method count and historical comparability success rate. Sites offering fewer than fifteen orthogonal methods rarely survive EMA scrutiny [9].

**Q: Does dual-sourcing make sense in the Biosimilar Contract Manufacturing Market?**
A: Yes for commercial-stage products above USD 200 million in projected sales. Second-source qualification costs USD 15–25 million but eliminates single-site regulatory and geopolitical exposure [11].

**Q: How do perfusion and fed-batch platforms compare for follow-on antibodies?**
A: Perfusion delivers higher volumetric productivity and a smaller footprint; fed-batch offers simpler validation and broader regulatory precedent. Most sponsors still choose fed-batch for first commercial programs [5].

**Q: What regulatory nuance most often delays approval?**
A: Extractables and leachables data from single-use components. Regulators increasingly demand component-specific studies rather than vendor-supplied generic packages [21].

**Q: Which emerging use cases will reshape the Biosimilar Contract Manufacturing Market after 2032?**
A: Antibody-drug conjugate and bispecific follow-ons. Both require conjugation suites and dual-chain expression systems that fewer than a dozen sites worldwide currently operate [3].

**Q: What integration challenge derails multi-site programs most often?**
A: Data harmonisation across differing manufacturing execution systems. Sponsors who mandate a common electronic batch record schema at contract signature avoid months of reconciliation later [20].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/biosimilar-contract-manufacturing-market-11903*